Genmab A (GMAB) Free Cash Flow (2018 - 2026)
Genmab A (GMAB) posted Free Cash Flow of $3.0 million for Q1 2026, down 99.66% on a QoQ basis from $885.0 million in Q3 2025, and down 98.95% year-over-year from $287.0 million in Q1 2025.
Genmab A (GMAB) Free Cash Flow (2018 - 2026) Analysis & Trends
Genmab A's Free Cash Flow history runs 6 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- Quarterly Free Cash Flow fell 98.95% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 15.39% YoY) and the FY2025 annual result came in at $1.1 billion, up 2.04% from the prior year.
- Free Cash Flow was $3.0 million for Q1 2026 at Genmab A, down from $885.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $885.0 million in Q3 2025 and bottomed at $3.0 million in Q1 2026.
- A 3-year average of $416.9 million and a median of $349.0 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow jumped 31.05% — and 2026, when it sank 98.95%.
- Genmab A's Free Cash Flow stood at $737.0 million in 2024, then rose by 20.08% to $885.0 million in 2025, then plunged by 99.66% to $3.0 million in 2026.
- Business Quant data shows GMAB's Free Cash Flow at $3.0 million in Q1 2026, $885.0 million in Q3 2025, and $349.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Jun 30, 2025 | 349.00 Mn |
| Jun 30, 2025 | 349.00 Mn |
| Mar 31, 2025 | 287.00 Mn |
| Mar 31, 2025 | 287.00 Mn |
| Sep 30, 2024 | 737.00 Mn |
| Sep 30, 2024 | 737.00 Mn |
| Jun 30, 2024 | 438.00 Mn |
| Jun 30, 2024 | 438.00 Mn |
| Mar 31, 2024 | 219.00 Mn |
| Mar 31, 2024 | 219.00 Mn |
| Sep 30, 2020 | 5,078.00 |
| Sep 30, 2020 | 5,078.00 |
| Dec 31, 2019 | 319.00 |
| Dec 31, 2019 | 319.00 |
| Sep 30, 2019 | 319.07 Mn |
| Sep 30, 2019 | 319.07 Mn |